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To investigate the long-term usefulness of immunosuppressive therapy (IST) for Japanese 
patients with lower-risk myelodysplastic syndromes, we retrospectively analysed 29 MDS 
patients who were treated with cyclosporine A alone or with anti-thymocyte globulin at a 
single institute in Japan. A total of 58.6% of patients showed hematological response to 
IST. Overall survival of all patients was 74.5% at five years and 48.3% at 10 years. The 
major adverse event was the elevation of creatinine level (grade 1 and 2). Eleven patients 
were still on IST at the time of analysis with, at least, some clinical benefits. Pneumonia 
was the most frequent cause of death (eight of 12 deaths), followed by bleeding (three of 
12); most of the patients who died were non-responders. The presence of paroxysmal 
nocturnal hemoglobinuria–type cells was significantly associated with both response to 
IST and long-term survival by univariate analysis. The 10-year overall survival of 
responders (72.2%) was significantly superior to that of non-responders (15.6%, P<0.0001). 
These results suggest that IST using cyclosporine A provides long-term benefit for 













Myelodysplastic syndromes (MDS) are clonal haematopoietic disorders characterized by 
cytopenia with ineffective hematopoiesis and transformation to acute leukemia. Although 
genetic abnormalities in stem cells play important roles, the precise pathophysiology of 
MDS is unclear. For example, in some cases, ineffective hematopoiesis appears to be 
caused, at least partly, by an immunological mechanism [1]. Reflecting these complicated 
disease pathophysiology, the clinical features of MDS including prognosis are quite 
heterogeneous, which necessitates a system of prognostic evaluation other than 
classification of MDS. The International Prognostic Scoring System (IPSS) is widely used 
to classify MDS patients into four risk categories [2], and the IPSS has been recently 
revised (IPSS-R) [3]. In general, different treatment strategies are taken for those with 
“lower-risk” and “higher-risk” patients. Since hematopoietic stem cell transplantation 
(HSCT) is the only curative treatment for MDS, HSCT is the first option for patients with 
high risk of leukemia transformation. However, MDS patients are tend to be elderly, and 
most of them be unable to undergo this procedure; therefore, treatments other than HSCT 
are needed. In terms “lower-risk” patients most of whom are categorized as low or 
intermediate-1 risk by IPSS, improvement of ineffective hematopoiesis is the major aim of 
the treatment,.  
Immunosuppressive therapies (IST) with anti-thymocyte globulin (ATG) and 
cyclosporine A (CsA) are used for patients with aplastic anaemia and lower-risk MDS [4-8]. 
Molldrem et al. [9]reported that by ATG administration, 34% of treated MDS patients 
achieved transfusion independency. Lim et al. [10] reported the response rate of MDS 
patients for ATG as 42% with a 3-year survival rate of 85% among responders, which was 
not statistically different from that of non-responders (56%). IST with CsA alone had a 
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response rate of 50% to 80% [11-14]. The combination of ATG and CsA exhibited a higher 
response rate than ATG alone (45% vs. 21%). Importantly, the median survival time was 
significantly longer with IST (8.2 years) than with supportive care alone (5.2 years) [15, 
16]. Clinical markers can be used to predict the response to IST for MDS patients. For 
example, the United States National Institutes of Health has used patient age, history of 
blood transfusion, and HLA-DR status to predict the efficacy of IST [16].  
These reports strongly suggest that IST is beneficial for lower-risk MDS patients; 
however, reports with long-term observation for Japanese patients are rare. In this 
article, we evaluated the long-term outcome of IST for MDS patients treated at a 
single institute in Japan. 
 
Patients and Methods 
 
Patients 
This is a retrospective study of MDS patients treated with IST at Nagasaki University 
Hospital from January 1995 to December 2012. This analysis was performed as of 
March 2013. The diagnosis of MDS was made by clinical features, hematological 
data of peripheral blood and bone marrow, and cytogenetics, following the 
French-American-British classification [17] and the World Health Organization 
(WHO) classification [18]. In our institute, IST was applied to MDS patients with 
cytopenia with dependency on transfusions of red blood cells (RBCs) or platelets, or 
neutropaenia [absolute neutrophil count (ANC) < 0.5 × 109 / L], and classified by 
IPSS as low, intermediate (int) -1 or int-2 (only with less than 5% blasts in the bone 
marrow) risk. All patients were ineligible for HSCT because of old age, 
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complications, a lack of suitable donors, or patient’s choice. 
Marrow cellularity was assessed by core biopsy, bone marrow clot section, and 
magnetic resonance imaging findings. Hypocellular marrow was defined as bone 
marrow cellularity of less than 20% with which MDS patients were also included in 
this study. Karyotype was assessed by conventional G-band cytogenetics. RBCs and 
neutrophils that lacked CD55 and CD59 expression were defined as paroxysmal 
nocturnal hemoglobinuria (PNH)–type cells, which were detected by flow cytometry 
with monoclonal antibody specific to these antigens [19]. Blood samples of patients 
obtained after 2008 underwent high-resolution two-colour flow cytometry to detect 
PNH-type cells, as previously reported [20]. PNH-type cells were considered present 
if they were detected in more than 0.003% of granulocytes and more than 0.005% of 
RBCs in the high-resolution setting. The Ham’s test was performed to detect PNH 
clones in some cases. HLA-DRB1 allele status and the presence of PNH-type cells 
were assessed before or after the initiation of IST. Informed consent was obtained 
from all patients.  
Transfusion dependence was defined as the requirement for at least 2 units of RBCs 
per month to maintain hemoglobin values of 90 g/L or less, according to the 
International Working Group criteria [21]. 
 
Treatment 
All patients received oral CsA at doses ranging from 2-6 mg/kg/day to maintain a 
trough blood concentration of 150-250 ng/mL. CsA was continued as long as no 
major toxicities occurred, and the dose was also adjusted by the serum creatinine 
value. Some patients received CsA and intravenous horse ATG (Lymphoglobuline, 
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Genzyme) at a dose of 10-15 mg/kg/day for 5 days. Patients with neutropenia (less 
than 0.5×109/L) received granulocyte-colony stimulating factor until ANC increased 
to more than 0.5×109/L. For some patients who showed inadequate response to CsA, 
tacrolims was administered at a dose needed to maintain a trough concentration of 
5-10 ng/mL.  
 
Response criteria 
Response criteria were defined according to the International Working Group 
response criteria [21] with minor modifications. We evaluated the response using the 
data obtained at the time of best response. Complete remission (CR) was defined as 
the improvement of all three lineages of peripheral blood parameters with 
hemoglobin ≥110 g/L, platelet count ≥100×109/L, and ANC ≥1.0×109/L with no 
blasts in peripheral blood and blasts in bone marrow less than 5%. Partial remission 
(PR) was defined as normalization of peripheral blood counts and at least 50% 
reduction of marrow blasts. Hematological improvement (HI) was defined as: (1) 
HI-erythroid (HI-E), an increase of hemoglobin level more than 15 g/L or reduction 
of blood transfusion by at least 4 RBC units during 8 weeks; (2) HI-platelet (HI-P), 
an increase of platelet count more than 3.0×109/L for patients starting with 
>2.0×109/L, or an increase of more than 2.0×109/L and by at least 100% for patients 
starting with <2.0×109/L; and (3) HI-neutrophil (HI-N), an increase of ANC more 
than 0.5 ×109/L or by at least 100%. Relapse after CR, PR, or HI was defined as a 
reduction of ≥50% from the maximal response level for ANC or platelets, a reduction 





Continuous variables of the patient subgroups were compared by using the Mann-Whitney 
rank-sum test or Student's t-tests. Percentages were compared with the Chi-squared test or 
the Fisher's exact test. Overall survival (OS) was estimated from the start of treatment to 
the time of death, HSCT, or last follow-up. OS was calculated by using the Kaplan-Meier 
method [22], and the log-rank test or Gehan-Breslow-Wilcoxon test was used to evaluate 
differences between survival distributions. P values less than 0.05 were considered 
statistically significant. Statistical analyses were performed with GraphPad Prism 6.01 




Patients and treatment 
Pre-treatment patient characteristics are shown in Table 1. We recruited 29 patients 
with a median follow-up of 6.7 years (range, 0.50-18.0 years). There were 14 men 
and 15 women, and the median age was 60 years (range, 31 to 83 years). 
Hemoglobin levels were less than 90 g/L in all patients. Twenty-two patients (76%) 
had received RBC transfusions before the initiation of IST. All patients except three 
had platelet counts less than 100 ×109/L. ANC was less than 1.0×109/L in 18 patients 
(62%).  
Five patients (17.2%) had hypocellular marrow. Based on the IPSS-R cytogenetics 
classification system, karyotypes of most patients were in ”good” and “intermediate” 
categories (21 patients, 72.4%, and 6 patients, 20.7%, respectively). Although all but 
two were in Int-1 category by IPSS, IPSS-R,differentiated four patients (13.8%) as 
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low, 20 patients (69.0%) as intermediate, and five patients (17.2%) as high risk. 
Human leukocyte antigen (HLA)–DRB1 status was tested in 27 patients. Ten patients 
had at least one allele of HLA-DRB1* 1501, and six patients had DR15 but their 
DRB1* was 1502, not 1501. 
Twenty-three patients were screened for PNH-type cells, and they were found in 12 
patients; 7out of 11 patients tested by high-resolution two-colour flow cytometry, 4 
out of 11 patients tested by ordinary flow cytometry, and one by Ham test.  
Treatment choice of CsA alone or CsA with ATG was determined by the attending 
physicians who considered age, presence of infection, organ function, and general 
condition of patients. Although we intended to continue IST for at least 6 months, the 
duration of IST was 6 months or less in seven patients. Two patients could not 
continue to recieve IST because of complications (elevation of creatinine, and 
interstitial pneumonia), and five patients discontinued IST because of no effect. At 
the time of this analysis, 11 responders out of 29 patients were still receiving IST 
(treatment duration, 0.6 to 16.1 years).  
 
Response 
Eight patients (27.6%) achieved CR, and no patients had PR. Nine patients (31%) 
achieved some hematological improvement, resulting in an overall response rate of 
58.6% (Table 2). HI-E was observed in 16 of 29 patients (55%) with anemia. Twelve 
of 26 patients (46.2%) with thrombocytopenia achieved HI-P, and 9 of 18 patients 
with neutropaenia (50%) showed HI-N. One patient who did not respond to IST 
received allogeneic bone marrow transplantation from a suitable unrelated donor 4.8 
years after discontinuation of IST. Tacrolimus was administered to 3 patients who 
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lost response to CsA and to 3 patients for whom CsA had no effect. One patient who 
did not respond to CsA achieved CR by tacrolimus. Hematological relapse occurred 
in 9 of 17 responders. Six of these patients had to discontinue or reduce the dose of 
CsA before relapse due to the elevation of creatinine level. 
There were no statistically significant differences in age, WHO subtype, marrow 
cellularity, IPSS-R or HLA DRB1*1501 status between responders (CR and HI) and 
non-responders. There was no specific karyotype that associated with responses to 
IST, either. However, the presence of PNH-type cells was significantly predictive of 
the response to IST (Table 2). The presence of PNH-type cells correlated with 
HLA-DRB1 *1501, but not with other factors (Table 3). 
 
Survival 
Five and 10-year OS was 74.5%, and 48.3%, respectively (Fig. 1). Median survival 
time was 8.6 years. In one patient that stopped IST after 5 months without response, 
leukemia progression occurred 3.8 years after discontinuation of IST. Five- and 
10-year OS among responders was 100% and 72.7%, respectively, which was 
significantly better than those among non-responders (41.7% and 15.6%, respectively. 
P<0.0001, Fig. 2). Factors such as marrow cellularity, IPSS category, IPSS-R 
category and blood transfusion status were not significant predictors for long-term 
survival. OS of patients with PNH-type cells was better (but not statistically 
significantly) than patients without PNH-type cells (Fig. 3). There were 17 patients 
that survived more than 5 years (long-term survivors). Among long-term survivors, 5 
died. One patient received allogeneic HSCT, and one patient was lost for the 
follow-up. Except for those died, transplanted, and lost follow-up, eleven out of 15 
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patients had continued receiving IST. All patients who were on IST showed various 
levels of clinical benefit of IST continuously, though some of them lost CR or HI by 
definition.  
 
Adverse events and cause of death 
Nine patients experienced elevated creatinine levels and subsequently required 
reduction of CsA dose, however, there were no grade 3 or 4 acute renal toxicities. 
Two patients developed interstitial pneumonia. Eight patients died of pneumonia 
(one of them had also systemic bleeding), 3 patients of bleeding (two cerebral, one 
gastrointestinal), and one died of an unknown cause.  
 
Discussion 
In this study, we reported the long-term results of IST for MDS patients (median 
observation period, 6.7 years). The overall response rate was 58.6%, and the median 
survival time was 8.6 yeas for all patients in this study. Considering that most of the 
patients (27 of 29 patients, 93.2%) in this study were in the Int-1 category of IPSS of 
which median survival time was 3.5 years [2], it is suggested that IST for lower-risk 
MDS is beneficial even for survival as reported by others. [16] These results 
confirmed previous reports that IST is a treatment option for MDS, in particular for 
cytopenia of lower-risk MDS patients, in which survival could be prolonged.   
Response rates to IST varied widely by each reports from less than 30% up to 60% 
[5,7, 23]. This might reflect the difference in each study, such as drugs used for IST, 
background of patients, and also the observation period. In this study, 24 out of 29 
patients were treated with CsA, alone. Though IST using CsA alone seemed to 
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provide inferior efficacy to IST using ATG with or without CsA [16, 24], our results 
showed certain efficacy of IST with CsA alone for Japanese patients with MDS.  It 
is not clear whether response to IST would be different among ethnic groups, 
Shimamoto et al. [12] reported relatively high response rate for Japanese by CsA 
alone.  In the present study, which had a very long observation time for most of the 
patients, 17 of 29 patients (58.6%) showed a clinical response to IST. Response rates 
between patients administered CsA alone and those received ATG and CsA did not 
differ. Six patients who did not respond to CsA or lost their response to CsA received 
tacrolimus after CsA, and one patient achieved a CR that was maintained for 9 years. 
Considering diverse reports from many groups, it is necessary to collect data on IST 
using various immunosuppressive agents for Japanese MDS patients.  
PNH-type cells are present in 4-10% of patients with MDS [10,19, 25]. By using 
sensitive flow cytometry [26], PNH-type cells were detected in 12 of 23 patients 
(52.1%) in this series. Wang et al. [20] demonstrated that seven of nine MDS-RA 
patients with PNH-type cells responded to CsA, suggesting PNH-type cells as a 
response marker. Ishikawa et al. [14] reported that the presence of PNH-type cells 
was associated with the platelet response to IST. It was also true in our results, 
showing the presence of PNH-type cells as a statistically significant predictor of 
hematological response and good prognosis. Since methodological improvements 
have changed the sensitivity for PNH cells, it would be interesting to re-evaluate its 
clinical meaning with long-term observation. Although our data came from a 
retrospective analysis of a limited number of cases, by reflecting the difference in 
10-year survival rates of responders and non-responders (72.2% and 15.6%, 
respectively. P<0.0001), univariate analysis revealed that the response to IST and 
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presence of PNH-type cells were predictive factors for long-term survival.  HLA 
subtype (DR 15), which was reported previously [27], did not predict response. The 
recently published IPSS-R divides cases into 3 categories (low-risk, 4 cases; 
intermediate-risk, 20 cases; high-risk, 5 cases), however, IPSS-R category did not 
ponse.  Bone marrow cellularity was not selected as a predictor of response in this 
study, which was shown to have predictive value for IST. Considering 3 out of 5 
cases with hypoplastic MDS responded to IST in our series, the importance of 
cellularity would be underestimated because of the small number of cases of this 
group. 
 In summary, our study with long-term observation supports previous reports 
showing the usefulness of IST for Japanese patients with lower-risk MDS. 
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Fig 1.  Overall survival of all patients. Five-year OS was 74.5%, and 10-year OS 
 was 48.3% in all patients. Median survival was 8.6 years. 
 
Fig 2.  Overall survival of responders (CR and HI) and non-responders. Five- and  
10-year OS among responders was 100% and 72.7%, and those among 
 non-responders were 41.7% and 15.6%, respectively. 
 




















































Table 1.   Patient characteristics 
 no (%), [range] 
No.of patients     29 
Median age, years [range] 60 [31- 83] 
Sex  
  Male 14 (48.5) 
  Female 15 (51.7) 
Median Hb, g/L [range]                62 [46-90] 
Median ANC, ×109/L [range] 0.9 [0.33-2.70] 
Median platelet count, ×109/L [range] 19 [4-385] 
Bone marrow cellularity   
  Hypo  5 (17.2) 
  Normo/hyper 24 (82.8) 
RBC transfusion before IST 22 (75.9) 
Cytogenetics category according to IPSS-R  
  Very good 1 (3.4) 
  Good                        21 (72.4) 
  Intermediate 6 (20.7)  
  Poor 1 (3.4) 
FAB  
RA 28 (96.6) 
  RARS                    1 (3.4) 
WHO 2008  
  RA 12 (41.4) 
RCMD 17 (58.6)  
IPSS risk category  
  Low 1 (3.4) 
Int-1 27 (93.2) 
  Int-2 1 (3.4) 
IPSS-R risk category  
  Low 4 (13.8) 
  Int-1 20 (69.0) 
  High 5 (17.2) 
PNH- type cells  
  Present 12 (41.4) 
Absent 11 (37.9) 
  Test not performed 6 (20.7) 
HLA DRB1  
  1501  10 (34.5) 
  1502 (without 1501) 6 (20.7) 
  Other 11 (37.9) 
  Test not performed 2 (6.9) 
Treatment  
  CsA 24 (82.8) 
  ATG+CsA 5 (17.2) 














Table 2.   Comparison of characteristics of patients between responders (CR and HI) and 
non-responders 
    Responder 
  CR     HI 
Non- 
responder 
P  (Responder vs. 
non-responder) 
No. of patients 8 9 12  
Median age   (years) 58.5 64 59 0.870 
      (range) 31-83 56-69 32-71  
WHO     
  RA 3 6 5 0.710 
  RCMD 5 3 7  
IPSS-R     
  Low 0 2 2 0.931 
  Int-1 7 5 8  
  High 1 2 2  
RBC transfusion     
  Yes 7 4 11 0.095 
  No 1 5 1  
Median Hb, g/L    








Median ANC, ×109/L 0.87 0.90 1.001 0.989 
(range) (0.38-2.48) (0.6-2.7) (0.33-2.67)  
Median platelet 
count, × 109/L   
20 14 19 0.834 
(range) (0.5-11.8) (0.5-5.7) (0.4-38.5)  
Bone marrow 
cellularity 
    
   Hypo 1 2 2 1.000 
  Normo/hyper 7 7 10  
HLA DRB1       










  Other 1 4 6 (15 vs. others) 
  Test not 
performed 
1 1 0  
Cytogenetics 
(IPSS-R) 
    
    Very Good 0 1 0 0.512 
    Good 6 6 9  
    Intermediate 2 2 2  
    Poor 0 0 1  
 PNH-type cells     
    Present 8 3 1 0.002 
    Absent 0 3 8  
  Test not performed 0 3 3  
Treatment     
    CsA 5 8 11 1.000 
    ATG +CsA 2 1 2  
    Tacrolimus 1 0 6  
 
Table 3.  Patient characteristics by the presence of PNH-type cells 
 With PNH-type cells Without PNH-type cells p 
No. of patients 12 11  
Median age (years, range) 61(31-83)           59 (40-71) 0.529 
WHO    
   RA 5 5 1.000 
   RCMD 7 6  
IPSS-R    
   Low 1 2 0.579 
   Int-1 9 6  
   High 2 3  
RBC transfusion     
   Yes 10 8 0.617 
   No 2 3  
Bone marrow cellularity    
   Hypo 1 3 0.231 
   Normo / hyper 11 8  
HLA DRB1    
   1501and/or 1502 10 3 0.008 
   Other 1 8 (15 vs. others) 
   ND 2 0  
Cytogenetics (IPSS-R)    
   Very good 0 1 0.865 
   Good 7 6  
   Intermediate 3 3  
   Poor 2 1  
 
 
 
 
 
 
 
